Home Healthcare Biotechnology Infectious Disease Molecular Diagnostics Market

Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Services), By Applications (Respiratory Diseases, Tuberculosis, Meningitis, Gastrointestinal Tract Infections, HPV, Sexually Transmitted Infections, Sepsis, Drug Resistance Disease, Other Infectious Diseases), By Technology (Polymerase chain reaction (PCR), In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Chips and Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification, Others), By End-User (Hospitals, Clinics, Diagnostics Laboratories, Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR5231DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Infectious Disease Molecular Diagnostics Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Instruments
    2. Reagents
    3. Services
  2. Infectious Disease Molecular Diagnostics Market, By Applications 2022-2034 (USD MILLION/ Units)
    1. Respiratory Diseases
    2. Tuberculosis
    3. Meningitis
    4. Gastrointestinal Tract Infections
    5. HPV
    6. Sexually Transmitted Infections
    7. Sepsis
    8. Drug Resistance Disease
    9. Other Infectious Diseases
  3. Infectious Disease Molecular Diagnostics Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Polymerase chain reaction (PCR)
    2. In Situ Hybridization
    3. Isothermal Nucleic Acid Amplification Technology (INAAT)
    4. Chips and Microarrays
    5. Mass Spectrometry
    6. Sequencing
    7. Transcription Mediated Amplification
    8. Others
  4. Infectious Disease Molecular Diagnostics Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Clinics
    3. Diagnostics Laboratories
    4. Research Institutes
  5. Regional Infectious Disease Molecular Diagnostics Market
    1. North America
      1. North America Infectious Disease Molecular Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Instruments
        2. Reagents
        3. Services
      2. North America Infectious Disease Molecular Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Respiratory Diseases
        2. Tuberculosis
        3. Meningitis
        4. Gastrointestinal Tract Infections
        5. HPV
        6. Sexually Transmitted Infections
        7. Sepsis
        8. Drug Resistance Disease
        9. Other Infectious Diseases
      3. North America Infectious Disease Molecular Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase chain reaction (PCR)
        2. In Situ Hybridization
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        4. Chips and Microarrays
        5. Mass Spectrometry
        6. Sequencing
        7. Transcription Mediated Amplification
        8. Others
      4. North America Infectious Disease Molecular Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
      5. U.S.
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      6. Canada
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
    2. Europe
      1. Europe Infectious Disease Molecular Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Instruments
        2. Reagents
        3. Services
      2. Europe Infectious Disease Molecular Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Respiratory Diseases
        2. Tuberculosis
        3. Meningitis
        4. Gastrointestinal Tract Infections
        5. HPV
        6. Sexually Transmitted Infections
        7. Sepsis
        8. Drug Resistance Disease
        9. Other Infectious Diseases
      3. Europe Infectious Disease Molecular Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase chain reaction (PCR)
        2. In Situ Hybridization
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        4. Chips and Microarrays
        5. Mass Spectrometry
        6. Sequencing
        7. Transcription Mediated Amplification
        8. Others
      4. Europe Infectious Disease Molecular Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
      5. U.K.
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      6. Germany
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      7. France
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      8. Spain
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      9. Italy
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      10. Russia
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      11. Nordic
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      12. Benelux
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      13. Rest of Europe
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
    3. APAC
      1. APAC Infectious Disease Molecular Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Instruments
        2. Reagents
        3. Services
      2. APAC Infectious Disease Molecular Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Respiratory Diseases
        2. Tuberculosis
        3. Meningitis
        4. Gastrointestinal Tract Infections
        5. HPV
        6. Sexually Transmitted Infections
        7. Sepsis
        8. Drug Resistance Disease
        9. Other Infectious Diseases
      3. APAC Infectious Disease Molecular Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase chain reaction (PCR)
        2. In Situ Hybridization
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        4. Chips and Microarrays
        5. Mass Spectrometry
        6. Sequencing
        7. Transcription Mediated Amplification
        8. Others
      4. APAC Infectious Disease Molecular Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
      5. China
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      6. Korea
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      7. Japan
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      8. India
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      9. Australia
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      10. Singapore
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      11. Taiwan
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      12. South East Asia
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      13. Rest of Asia-Pacific
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
    4. Middle East and Africa
      1. Middle East and Africa Infectious Disease Molecular Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Instruments
        2. Reagents
        3. Services
      2. Middle East and Africa Infectious Disease Molecular Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Respiratory Diseases
        2. Tuberculosis
        3. Meningitis
        4. Gastrointestinal Tract Infections
        5. HPV
        6. Sexually Transmitted Infections
        7. Sepsis
        8. Drug Resistance Disease
        9. Other Infectious Diseases
      3. Middle East and Africa Infectious Disease Molecular Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase chain reaction (PCR)
        2. In Situ Hybridization
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        4. Chips and Microarrays
        5. Mass Spectrometry
        6. Sequencing
        7. Transcription Mediated Amplification
        8. Others
      4. Middle East and Africa Infectious Disease Molecular Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
      5. UAE
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      6. Turkey
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      7. Saudi Arabia
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      8. South Africa
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      9. Egypt
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      10. Nigeria
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      11. Rest of MEA
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
    5. LATAM
      1. LATAM Infectious Disease Molecular Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Instruments
        2. Reagents
        3. Services
      2. LATAM Infectious Disease Molecular Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Respiratory Diseases
        2. Tuberculosis
        3. Meningitis
        4. Gastrointestinal Tract Infections
        5. HPV
        6. Sexually Transmitted Infections
        7. Sepsis
        8. Drug Resistance Disease
        9. Other Infectious Diseases
      3. LATAM Infectious Disease Molecular Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase chain reaction (PCR)
        2. In Situ Hybridization
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        4. Chips and Microarrays
        5. Mass Spectrometry
        6. Sequencing
        7. Transcription Mediated Amplification
        8. Others
      4. LATAM Infectious Disease Molecular Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
      5. Brazil
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      6. Mexico
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      7. Argentina
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      8. Chile
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      9. Colombia
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
      10. Rest of LATAM
        1. Instruments
        2. Reagents
        3. Services
        4. Respiratory Diseases
        5. Tuberculosis
        6. Meningitis
        7. Gastrointestinal Tract Infections
        8. HPV
        9. Sexually Transmitted Infections
        10. Sepsis
        11. Drug Resistance Disease
        12. Other Infectious Diseases
        13. Polymerase chain reaction (PCR)
        14. In Situ Hybridization
        15. Isothermal Nucleic Acid Amplification Technology (INAAT)
        16. Chips and Microarrays
        17. Mass Spectrometry
        18. Sequencing
        19. Transcription Mediated Amplification
        20. Others
        21. Hospitals
        22. Clinics
        23. Diagnostics Laboratories
        24. Research Institutes
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.